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Introduction: Trimethylaminuria is a rare inherited disorder due to decreased metabolism of dietary-derived
trimethylamine by flavin-containing monooxygenase 3. Several single nucleotide polymorphisms of the flavin-containing
monooxygenase 3 gene have been described and result in an enzyme with decreased or abolished functional activity for
trimethylamine N-oxygenation thus leading to trimethylaminuria.
Case presentation: Here we investigated an Italian family in which the proband was a 7-year-old girl with suspected
trimethylaminuria, by flavin-containing monooxygenase 3 gene direct sequencing and urinary determination of
trimethylamine and trimethylamine N-oxide. Genetic analysis found that, as with her parents and one of her two
brothers, the proband carried three polymorphisms: c.472 G>A p. E158K (rs 2266782) in exon 4, c.627+10 C>G
(IVS5+10G>C) (rs 2066534) and c.485-21 G>A (IVS4-22G>A) (rs 1920149) in intronic regions.
Conclusions: Despite the same genotypic condition only the girl had symptoms attributable to the
trimethylaminuria. The suspicion is that she has transient childhood trimethylaminuria. Therefore, we bring
attention to the importance of genetic testing and eventual determination of urinary trimethylamine and
trimethylamine N-oxide as instruments to offer to clinicians in the management of these pediatric patients.
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Flavin-containing monooxygenase 3 (FMO3) is one of five
members of a flavin-containing monooxygenases (FMOs)
gene family whose gene products are localized in the endo-
plasmic reticulum of many tissues where they catalyze the
nicotinamide adenine dinucleotide phosphate -dependent
oxidative metabolism of many drugs, pesticides, dietary
components and other foreign compounds.
FMO3 is the major adult hepatic isoform whereas
FMO1 is the major fetal isoform. Both are subject to de-
velopmental and tissue-specific regulation, with a devel-
opmental switch in the expression of FMO1 and FMO3* Correspondence: crinaldi@unime.it
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unless otherwise stated.genes taking place in the liver [1,2]. So, FMO1 is the
childhood form and FMO3 is expressed in late child-
hood and into adulthood. FMO3 is responsible for N-oxida-
tion of a malodorous metabolite, trimethylamine (TMA), to
the non-odorous trimethylamine N-oxide (TMAO); it is
present in low abundance in fetal liver and it is expressed at
intermediate levels until 11 years of age with an increase in
its expression during puberty. TMA is derived from dietary
precursors, such as choline and lecithin, found in foods
such as egg yolk, liver, kidney, legumes, soybeans, peas,
shellfish, and salt-water fish via the action of bacteria in the
human gut.
More than 300 single nucleotide polymorphisms of the
human FMO3 have been reported [3] and over 40 of
these polymorphisms have been linked to trimethylami-
nuria (TMAU) also known as “fish odor syndrome”. Af-
fected individuals excrete excessive amounts of TMA inal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Primer pairs employed in polymerase chain
reaction analysis
Primer set Primer sequence Ta* Target
1 5'-ACCACACACTGTACTCAGA-3' 51°C Upstream
5'-GTCTACGTCCTGTCCAAC-3'
2 5'-GTAGGAGGCTGAGGCGGG-3' 52°C Exon1
5'-GTTTCACCATGTTGGTCA-3'
3 5'-GTGAGCTACCATACTCA-3' 52°C Exon2
5'-CTGTGTGCACACAGTGT-3'
4 5'-GATGACTGTAATTACTTGG-3' 52°C Exon3
5'-ATGAGAATCCAGTA-3'
5 5'-TGTAATATGTATCTTAATCAT-3' 43°C Exon4
5'-TGTCAGTTATGTGGCTA-3'
6 5'-CATTATTGTGACTGCATC-3' 50°C Exon5
5'-AACTCTTCTGTCAGTAAC-3'
7 5'-GTAATAGATCCATTCCTCA-3' 50°C Exon6
5'-GCTTACAGGACATTAAG-3'
8 5'-TATATATGGACCAATAAAAC-3' 50°C Exon7
5'-GTCACTGGCATTCATCT-3'
9 5'ACACCAATTAATGTAATTCA-3' 52°C Exon8
5'-TCTATGGAAATCCTACAC-3'
10 5'-TCTGTTCTGTTTCTACAC-3' 52°C Exon9
5'-GATGATTAGGTCAACAC-3'
11 5'-GTGTTGACCTAATCATC-3' 48°C Exon9
5'-CTGCAAATAGCTTATA-3'
*Annealing temperature.
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is not associated with mortality or morbidity, but psycho-
social consequences may be devastating. Two major forms
of TMAU have been described [4]: a primary genetic form
that causes decreased FMO3 function, and a secondary
one that is due to TMA or to a TMA-precursor overload.
It is an autosomal recessive disorder, but there are minor
forms of TMAU including an acquired TMAU with no
obvious FMO3 background, a transient childhood form,
and a transient form in women associated with menstru-
ation [5-7].
In this study we report a case of suspected TMAU in a
7-year-old girl.
Case presentation
An Italian 7-year-old girl with a TMAU-like phenotype
has come to our attention after her mother reported the
production of strong body odor. The child’s history re-
vealed that she is the third child of healthy, unrelated par-
ents. Her two brothers aged 16 and 10 years were both
apparently healthy.
All her hematological parameters and her biochemical
indices for renal, thyroid and liver function were within
the normal range.
TMAU was suspected and it was suggested that the
child’s DNA be examined for mutations in the FMO3
gene. The study was approved by our local ethics com-
mittee. Written informed consent was obtained from the
patient’s parents.
Molecular analysis of FMO3 gene in the index patient
and family members was performed. Genomic DNA was
extracted from heparinized peripheral blood of all family
members using the salting out method [8]. Upstream se-
quence, the non-coding exon 1 and each of the coding
exons (exons 2 to 9) of the FMO3 gene were amplified
from genomic DNA by polymerase chain reaction using
the primer pairs shown in Table 1.
PCR products were sequenced with the BigDye® Ter-
minator sequencing kit version 1.1 on the 377 ABI
PRISM® Sequencer Analyzer (Applied Biosystems).
We also analyzed urine samples from the proband and
all family members for the presence of TMA and TMAO.
A first urine sample was collected for 24 hours under nor-
mal dietary conditions (a diet not containing TMA-rich
foods) and a second was collected for 6 to 8 hours after a
300g marine fish meal.
Urine samples were acidified to pH 3.0 with formic
acid and stored at −20°C. Creatinine was measured by
the Jaffe reaction on an autoanalyzer.
Derivatization of TMA was carried out according to the
method by Johnson using ethyl bromoacetate as a deriva-
tive reagent [9,10]. Each sample was analyzed in duplicate.
Mutations analysis of nine exons of the FMO3 gene
was performed on all family members.The proband was found heterozygous for the previ-
ously reported polymorphism c.472 G>A p. E158K
(rs 2266782) in exon 4, and a G-to-A transition at codon
158 (GAG to AAG) resulting in a glutamic acid to lysine
substitution (Glu158 to Lys158).
E158K polymorphism reduces FMO3 catalytic activity
that appears to vary depending on the substrate [11-13].
Previous in vitro expression studies showed that the
K158 form of the protein is a poorer TMA N-oxygenator
than the E158 form.
In some populations, this variant was found in a high
degree of linkage disequilibrium with the E308G variant.
When present on the same allele, the E158K and E308G
exhibit an even more pronounced effect on FMO3 func-
tion [11], even leading to mild or transient forms of
TMAU [14].
The proband was heterozygous also for two polymor-
phisms in intronic regions: c.627+10 C>G (IVS5+10G>C)
(rs 2066534) and c.485-21 G>A (IVS4-22G>A) (rs 1920149).
The first, a variant of uncertain functional relevance,
was found in cis with E158K polymorphism [15] while the
second was an intronic A-to-G substitution at the −21
position from the acceptor splice site of exon [6,16]. The
Figure 1 Pedigree of the child with trimethylaminuria-like
phenotype and flavin-containing monooxygenase 3 haplotype
analysis of the child (arrow) and other family members. The
flavin-containing monooxygenase 3 complementary DNA sequence
from GenBank accession number NM_006894.5 was used as a
reference sequence where the A of the ATG translation initiation
start site represents nucleotide +1. N-oxidation metabolic ratios for
family members after a 300g marine fish meal.
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for the same variants while the younger brother did not
show any variation.
Since the latter was wild-type it is possible to deduce
that he has inherited the wild-type allele from each parent
and that c.472 G>A, c.485-21 G>A and c.627+10C>G
polymorphisms occurred in cis configuration on one of
the two FMO3 alleles of the father and mother.
On the basis of this it is possible to infer that the pro-
band and the elder of the two brothers, as well as the
parents, were compound heterozygotes for the threeTable 2 Urinary excretion of trimethylamine and trimethylam











Mother 104 5960 0.02 98.3
Father 70 1820 0.04 96.3
Proband 117 48 2.4 29.0
Brother1 20 600 0.03 97.0
Brother2 35 910 0.04 96
Normal ratio: TMA/TMAO = 0.0025 to 0.055 (>85% TMAO).
Affected ratio: TMA/TMAO >0.2 (<20% TMAO).
Abbreviations: Crn creatine, TMA trimethylamine, TMAO trimethylamine N-oxide.polymorphisms (Figure 1). However, among them, only
the proband showed a TMAU-like phenotype.
Therefore, we wanted to analyze the upstream region
of FMO3 gene in order to identify polymorphic variants
that could affect the enzymatic activity. No variants were
identified in any family members. Analysis of the urine
samples collected for 24 hours from both parents and
two brothers under normal dietary conditions (a diet not
containing TMA-rich foods such as fish or eggs) showed
the presence of relatively small amounts of TMA ex-
creted. The N-oxidation metabolic ratio (TMA/TMAO
ratio) for the four subjects ranged from 0.02 to 0.04.
For the proband the TMA excretion accounted for only
29.0% of total TMA excretion. The N-oxidation metabolic
ratio for the proband was 2.4, two orders of magnitude
greater than those observed for the parents and two
brothers (affected ratio TMA/TMAO >0.2).
After oral TMA challenge, the amount of urinary
TMA excreted as TMAO, in the parents and two broth-
ers remained high and it was very similar to the values
under normal dietary conditions. N-oxidation metabolic
ratio ranged from 0.02 to 0.04.
After oral TMA challenge, in the proband, TMAO ex-
cretion accounted for 19.4% of total TMA excreted
(Table 2).
Discussion
In this study we evaluated a 7-year-old girl with a clinical
suspicion of TMAU. Results of molecular genetic studies
revealed that she was heterozygous for three polymorphic
variants one of which, the c.472 G>A, is known to cause a
reduction in FMO3 enzymatic activity. Among the other
two variants, both intronic, the c. 485–21 G>A falls within
the intron 4 splice acceptor site. The variant results in an
increase in information content (Ri) suggesting that it
strengthens the respective splice site and potentially af-
fects the splicing [17]. Both the parents and one of the
two brothers had the same genotypic condition. However,ine N-oxide by the proband and family members under













480 19140 0.02 97
640 14000 0.04 95.6
738 178 4.1 19.4
225 5420 0.04 99.0
320 12220 0.02 97.0
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displays symptoms of TMAU.
This phenotypic manifestation was supported by data
on urinary determination of TMA and TMAO that show
an N-oxidation metabolic ratio for the proband equal to
2.4, two orders of magnitude greater than those observed
for the parents and two brothers.
In addition, no variants in the upstream region of
FMO3 gene have been identified in the proband, absent
in other family members, such as to justify this signifi-
cant reduction in enzyme activity.
Conclusions
The most likely explanation is that the proband has
transient childhood TMAU [18].
In fact, FMO3 and FMO1 are subject to developmental
and tissue-specific regulation and, in the liver, there is a
developmental switch in the expression of these genes:
FMO1 functional activity decreases in early childhood
time periods and a concomitant increase in functional ac-
tivity of FMO3 emerges [19].
FMO3 expression is detectable in most individuals by
1 to 2 years of age and it is expressed at intermediate
levels until approximately 11 years [2].
In the proband, a combination of one non-functional
FMO3 allele and immature expression of the other, func-
tional, FMO3 allele, may be sufficient to cause symptoms
of the disorder. As the proband develops, the expression
of her functional allele will increase and, consequently, her
symptoms should eventually disappear. After all this is
verifiable in the 16-year-old elder brother of the proband:
he has the same genotype as the proband and parents but
no TMAU symptoms. In this case, genetic factor(s) may
have less impact on this phenotype. The large majority of
cases with primary FMO3 deficiency will present in early
childhood and accurate diagnosis is essential for appropri-
ate genetic counselling and their long-term management.
Clinically, whether in the child or adult, TMAU cannot be
considered a benign or ‘social’ condition, early diagnosis is
important in children with TMAU so that appropriate
dietary therapy may be introduced as soon as possible. Al-
though initial indications of the disorder may be obtained
by analysis of a single urine sample, this is not always reli-
able, especially when the child is ingesting a diet low in
TMA precursors.
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